Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine
June 22, 2015 16:10 ET
|
Vical Incorporated
The Primary Endpoint of Shedding Rate was not Met
Conference Call and Webcast to be Held Today, June 22 at 5:00 pm ET
SAN DIEGO, June 22, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated...
Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients
May 21, 2015 06:30 ET
|
Vical Incorporated
SAN DIEGO, May 21, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 2 trial of its therapeutic cytomegalovirus (CMV) vaccine in solid...
Vical Reports First Quarter 2015 Financial Results and Progress in Key Development Programs
May 08, 2015 06:30 ET
|
Vical Incorporated
SAN DIEGO, May 8, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended March 31, 2015. Net loss for the first quarter of 2015 was $3.8...
Vical Announces News Release and Conference Call Schedule for First Quarter 2015 Financial Results
May 01, 2015 06:30 ET
|
Vical Incorporated
SAN DIEGO, May 1, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2015, before the opening...
Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative
April 22, 2015 06:30 ET
|
Vical Incorporated
Vical to receive $4 million under new contract with IPPOX Foundation, funded via a grant from the Bill & Melinda Gates Foundation, to supply plasmid DNA for HIV vaccine clinical...
Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference
April 21, 2015 06:30 ET
|
Vical Incorporated
A Vaxfectin®-formulated gB DNA vaccine induces antibodies that block cytomegalovirus entry into fibroblasts and epithelial cells in preclinical study
Data presented at the 5th...
Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
March 25, 2015 16:15 ET
|
Vical Incorporated
Development and potential commercial synergies with existing CMV program
Targeting Phase 1 initiation in first half of 2016
2015 cash burn guidance remains unchanged
SAN DIEGO, March...
Vical to Present at the 27th Annual ROTH Conference
March 05, 2015 06:00 ET
|
Vical Incorporated
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...
Vical Reports Fourth Quarter 2014 Financial Results and Progress in Key Development Programs
February 26, 2015 06:30 ET
|
Vical Incorporated
SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and twelve months ended December 31, 2014. Net loss for the fourth...
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2014 Financial Results
February 19, 2015 06:00 ET
|
Vical Incorporated
SAN DIEGO, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and twelve months ended December 31, 2014,...